Up a level |
Nathan, Paul, Hassel, Jessica C, Rutkowski, Piotr, Baurain, Jean-Francois, Butler, Marcus O, Schlaak, Max, Sullivan, Ryan J, Ochsenreither, Sebastian, Dummer, Reinhard, Kirkwood, John M et al (show 18 more authors)
(2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
NEW ENGLAND JOURNAL OF MEDICINE, 385 (13).
pp. 1196-1206.
Carvajal, Richard D, Nathan, Paul, Sacco, Joseph J, Orloff, Marlana, Hernandez-Aya, Leonel F, Yang, Jessica, Luke, Jason J, Butler, Marcus O, Stanhope, Sarah, Collins, Laura et al (show 4 more authors)
(2022)
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
Journal of Clinical Oncology, 40 (17).
1939-+.
Hassel, Jessica C, Piperno-Neumann, Sophie, Rutkowski, Piotr, Baurain, Jean-Francois, Schlaak, Max, Butler, Marcus O, Sullivan, Ryan J, Dummer, Reinhard, Kirkwood, John M, Orloff, Marlana et al (show 19 more authors)
(2023)
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
The New England journal of medicine, 389 (24).
pp. 2256-2266.